MEMORANDUM OF UNDERSTANDING

This Memorandum of Understanding (MoU) effective 23rd September 2022 is made by & between;

Rectitude Ethics Committee, the institutional Ethics Committee (IEC) of DNS Hospitals Pvt.Ltd. having its Registered Office at 14 Anoop Nagar, A. B. Road,Near L. I. G. Square, Indore 452008**, India**, established to ensure the rights, safety, well-being of human participants in research conducted [hereinafter referred to as the "**Reviewing Committee**" (which expression shall unless it be repugnant to the context or meaning thereof be deemed to mean and include its successors and permitted assigns)

AND

Dr. Amit Katlana, Professor – Department of Surgery, Index Medical College Hospital & Research Centre at Index City, NH – 59A, Near Khudel, Nemawar Road, Indore, Madhya Pradesh 452016, India [hereinafter referred to as the "**Investigator**" and Index Medical College Hospital & Research Centre, Indore as **"Institution"** (which expression shall unless it be repugnant to the context or meaning thereof be deemed to mean and include its representatives, agents and permitted assigns etc.)

AND

DNS Hospitals Pvt.Ltd., (In association with SRJ Healthcare Pvt. Ltd),

Indore, Madhya Pradesh 452008, India, a Company registered under the provisions of Indian Companies Act, NH/0282/MAR-2020, having its registered office at 14 Anoop Nagar, A. B. Road, Near L. I. G. Square, Indore acting through its Director, Rajesh Jain, being authorized to sign this Agreement (hereinafter referred to as the "Institute" which expression shall mean and include unless repugnant to the context, its successors and permitted assigns).

(Hereinafter individually "**Party**" or collectively "**Parties**")

WHEREAS the Reviewing Committee is recognized for its expertise and is mandated to review and monitor any and all types of research in which human subjects are involved.

Malwanchal University INDORE

College Address : Index City, Near Khudel, NH-59A, Nemawar Road, Dist., INDORE (M.P.)- 452 016 Ph. 0731-4013600
City Office : 104, Trishul Apartment, 5, Sanghi Colony, A.B. Road, INDORE - 452008 Phone : 0731-4215757, Fax : 0731-4044715
E-mail : medical@indexgroup.co.in, deanindex1@gmail.com I website : www.indexgroup.co.in,

WHEREAS THE Investigator shall in association with **Raptim Research Pvt. Ltd.,** (hereinafter called as **"Sponsor")** a Pharmaceutical company involved in research, development, manufacture and sale of pharmaceutical products for use in humans is desirous of conducting the Clinical Trial at Index Medical Hospital & Research Centre; A Multicentric, Open-label, Randomized, Two Period, Two Treatment, Two Sequence, Cross Over, Multiple Dose, Steady state Bioequivalence Study of Pazopanib tablets 200 mg of Eugia Pharma Specialities Limited (Test) with VOTRIENT® (pazopanib) tablets 200 mg of Novartis Pharmaceuticals Corporation, USA (Reference) in adult patients with advanced renal cell carcinoma already receiving Pazopanib HCl tablets in standard therapy, and who are tolerating a stable dosing regimen of 800 mg/day (4 × 200 mg) under fasting conditions.

AND WHEREAS the Investigator approached the Review Committee for review of the Study. In consideration of the mutual promises of the parties herein, and of the mutual covenants and conditions hereinafter set forth, the parties agree as follows:

1. Reviewing Committee shall review the study to be conducted by the investigator and evaluate the performance of the surgeon & his team and shall use its best efforts to deliver the finding and recommendations with a view to ensure the rights, safety, and well-being of human participants in research conducted.

2. The Parties represent and warrant that they each have the authority to enter into this Agreement. The Institution and/or Investigator will ensure the availability of and/or access to any resources necessary to perform the Clinical Trial at the Trial Site, including departments, facilities and Research Staff and support personnel, and the Principal Investigator represents that he/she holds the necessary registration and has the necessary qualifications, expertise and time to perform the Clinical Trial.

3. The Sponsor and the Investigator agree to perform the Clinical Trial in accordance with the terms and conditions of this Agreement and are expected to conduct the study in compliance with applicable local regulations, guidelines and standard operating procedures.

4. The Investigator and study team will report and update the Reviewing Committee about detailed status of study on a bi-monthly basis for the first year from site initiation and quarterly basis from second year till site close out or last patient last follow-up visit, whichever is earlier.

College Address : Index City, Near Khudel, NH-59A, Nemawar Road, Dist., INDORE (M.P.)- 452 016 Ph. 0731-4013600
City Office : 104, Trishul Apartment, 5, Sanghi Colony, A.B. Road, INDORE - 452008 Phone : 0731-4215757, Fax : 0731-4044715
E-mail : medical@indexgroup.co.in, deanindex1@gmail.com I website : www.indexgroup.co.in,

5. The Investigator and study team will report to the Reviewing Committee by email / letter (in standard detailed format) all Adverse Events, Serious Adverse Events and all deviations related to Protocol, related to applicable guidelines, related to local regulations and any other general, situational and any other deviation irrespective of severity of the effect of the deviation or event promptly. Any delay in the same may result in immediate suspension of conduct of the trial at the Investigator site and result in a for-cause audit and/or inspection.

6. Reviewing Committee will have access to all requested data of study subjects as and when required for review.

7. Reviewing Committee may conduct audit and/or inspection of the study conduct and related data as and when required.

8. Reviewing Committee expects information, notification, pre-initimation & pre-approval (wherever necessary) of any change or update in any of the study Protocol, documents, procedure or any other change in connection or in relation to the study.

9. In the event of any substantial amendments being made to the Protocol, the amendments shall be signed by the Investigator and shall be implemented by the Research Staff as required by the Sponsor or CRO after approval of the amendments by the Competent Authority and a favourable opinion of the Reviewing Ethics Committee.

10. Reviewing Committee needs to be informed of any protocol waiver granted to any subject; in case of any emergency/life threatening circumstances.

11. The Parties shall conduct the Clinical Trial in accordance with:
    a. the Agreement;
    b. the Protocol;
    c. the terms and conditions of the Clinical Trial Authorization granted by the Competent Authority and the opinion of the Reviewing Ethics Committee; and
    d. the applicable Laws.

Malwanchal University INDORE

5/11/22

College Address : Index City, Near Khudel, NH-59A, Nemawar Road, Dist., INDORE (M.P.)- 452 016 Ph. 0731-4013600
City Office : 104, Trishul Apartment, 5, Sanghi Colony, A.B. Road, INDORE - 452008 Phone : 0731-4215757, Fax : 0731-4044715
E-mail : medical@indexgroup.co.in, deanindex1@gmail.com I website : www.indexgroup.co.in,

Subject to the limitations set out hereinafter, Investigator shall indemnify, defend and hold harmless the Reviewing Committee, its representatives, members, agents & the assigners (the "Indemnitees") against all claims, demands, actions or proceedings (to include any settlements or ex-gratia payments made with the consent of the Parties hereto and reasonable legal and expert costs and expenses) made or brought (whether successfully or otherwise):

(i) by or on behalf of any Clinical Trial Subject in connection with personal injury or death arising out of the administration or use of the Investigational Product during or as a result of the Clinical Trial, or of any clinical intervention or procedure provided for or required by the Protocol, to which the Clinical Trial Subject would not have been exposed but for its participation in the Clinical Trial;

(ii) by Institution, the Principal Investigator or by or on behalf of a Clinical Trial Subject for compensation of reasonable and necessary medical costs and expenses incurred by the Clinical Trial Subject who has suffered personal injury as described in above.

INSURANCE

The Investigator and Institution will take out or maintain an insurance cover in respect of the potential liability of Investigator & Institution, the Research Staff, the Principal Investigator and any other employees and Agents involved with the conduct of the Clinical Trial pursuant to this Agreement. Institution shall produce on request the copies of Clinical Trial Agreement with the sponsor and insurance certificates, together with evidence that the policies to which they refer remain in full force and effect during the term of this Agreement and any period thereafter as may be required by mandatory law.

Further, the terms of any insurance or the amount of cover shall not relieve Institution or the Principal Investigator of any liabilities under this Agreement.

The Ethics Committee expressly disclaims any liability in connection with the content of the Protocol and the Investigational Product, including any liability for any product claim arising out of a condition caused by or allegedly caused by the administration of such product and willful and intentional misconduct of the study team.

The Principal Investigator shall make sure that the Clinical Trial Subjects (and/or their legal representatives) will, in accordance with applicable Law, be duly informed and that each give his/her audio-visual informed consent prior to participation in the Clinical Trial. Institution will provide Ethics Committee an opportunity to review the content of any Clinical Trial recruitment materials directed to potential Clinical Trial Subjects before such materials are used, regardless of medium.

Malwanchal University INDORE

College Address : Index City, Near Khudel, NH-59A, Nemawar Road, Dist., INDORE (M.P.)- 452 016 Ph. 0731-4013600
City Office : 104, Trishul Apartment, 5, Sanghi Colony, A.B. Road, INDORE - 452008 Phone : 0731-4215757, Fax : 0731-4044715
E-mail : medical@indexgroup.co.in, deanindex1@gmail.com I website : www.indexgroup.co.in.

In the event that the Ethics Committee reasonably believes there has been any research misconduct in relation to the Clinical Trial, Site Parties shall provide all reasonable assistance to any investigation into any alleged research misconduct undertaken by or on behalf of the Ethics Committee, the results of which the Party on whose behalf the investigation was undertaken shall, subject to any obligations of confidentiality, communicate to the Principal Investigator & Institution.

The investigator &/or Institution shall take appropriate measures and cause the Research Staff to take appropriate measures and corrective actions without delay as the Ethics Committee may reasonably require in order to solve all problems found and reported by the Trial Monitors and any of the aforesaid Auditors, by or on behalf the representatives of the Ethics Committee.

The Investigator and Study Team shall ensure that all procedures defined in the Protocol are complied with, so that all data generated at the Trial Site are reliable and have been processed correctly and will ensure that the content of the CRFs (Case Report Forms) will accurately reflect source documents.

CONFIDENTIALITY

The Parties agree that each will comply with their respective obligations as required under applicable privacy and data protection laws. The Institute and the Investigator will obtain the consent of each Research Subject for the use, processing, holding and transfer of their data to other countries that may not have same level of data protection as in India. It is the responsibility of Investigator and Institution to effect and maintain all registrations for the processing of Clinical Data as required by the applicable law and legislation. Each Party shall be responsible for its own processing of personal data in accordance with all law and regulations and with the informed consents obtained from Clinical Trial Subjects.

The Parties agree to adhere to the principles of medical confidentiality in relation to Clinical Trial Subjects.

The Receiving Party shall ensure that only those of its officers and employees (and those of its Affiliates and members of the Research Staff) and Agents directly concerned with the carrying out of this Agreement have access to the Confidential Information of the Disclosing Party. The Receiving Party shall take all practicable steps to ensure that such persons abide by the same obligations of confidentiality as apply to the Receiving Party under this Agreement. The Receiving Party undertakes to treat as strictly confidential and

5/11/22

College Address : Index City, Near Khudel, NH-59A, Nemawar Road, Dist., INDORE (M.P.)- 452 016 Ph. 0731-4013600
City Office : 104, Trishul Apartment, 5, Sanghi Colony, A.B. Road, INDORE - 452008 Phone : 0731-4215757, Fax : 0731-4044715
E-mail : medical@indexgroup.co.in, deanindex1@gmail.com I website : www.indexgroup.co.in.

not to disclose to any third party any Confidential Information of the Disclosing Party, except where disclosure is required by a regulatory authority or by law, in which case the

Receiving Party shall inform the Disclosing Party of such requirement and the information to be disclosed and Disclosing Party take reasonable steps to limit the scope of such disclosure. Notification will be within a reasonable time prior to being required to make the disclosure or if such time is not available, immediately upon becoming known of the requirement to disclose Confidential Information. The Receiving Party undertakes not to make use of any Confidential Information of the Disclosing Party, other than in accordance with this Agreement, without the prior written consent of the Disclosing Party.

The obligations of confidentiality and non-use set out in above clause hall not apply to information which:

a. is or becomes part of the public domain by any other means than a wrongful act or breach of this Agreement by the Receiving Party;

b. was or becomes in the Receiving Parties' lawful possession prior to the disclosure without restriction on disclosure as evidenced by written records;

c. has been independently developed by the Receiving Party without the use of Confidential Information of the Disclosing Party as evidenced by written records;

d. has been obtained by the Receiving Party from a third party who is not subject to a duty of confidentiality.

TERM AND TERMINATION

This Agreement shall come into effect upon the Effective Date and shall remain in force till the Study is completed and the Parties have discharged their obligations pursuant to this Agreement, unless and until terminated by any party.

Each Party may terminate this Agreement upon one month written notice to the other Parties with immediate effect in the following events:

a. if the approval by the Ethics Committee in charge of the Clinical Trial is not granted or irrevocably revoked;

b. if it can be reasonably concluded that the Clinical Trial must be terminated in the interests of the health of the Clinical Trial Subjects;

College Address : Index City, Near Khudel, NH-59A, Nemawar Road, Dist., INDORE (M.P.)- 452 016 Ph. 0731-4013600
City Office : 104, Trishul Apartment, 5, Sanghi Colony, A.B. Road, INDORE - 452008 Phone : 0731-4215757, Fax : 0731-4044715
E-mail : medical@indexgroup.co.in, deanindex1@gmail.com I website : www.indexgroup.co.in,

c. If it becomes apparent, following confirmation of the Ethics Committee, that continuation of the Clinical Trial cannot serve a scientific purpose, and this is notified to the Ethics Committee;

d. if the Sponsor and/or the Institution and/or the Investigator become or are declared insolvent or a petition in bankruptcy has been filed against it or if one of them is dissolved;

e. if circumstances beyond a Party's control occur that render continuation of the Clinical Trial unreasonable.

f. if one of the parties fails to comply with the obligations arising from the Agreement and, if capable of remedy, is not remedied within 15 days after receipt of notice from the other Party specifying the non-compliance and requiring its remedy, unless failure to comply is not in reasonable proportion to the premature termination of the Clinical Trial.

In all circumstances causing the early termination of this Agreement pursuant to clauses above, the Sponsor shall confer with the Principal Investigator and Institution shall use their best endeavors to minimize any inconvenience or harm to Clinical Trial Subjects caused by the premature termination of the Clinical Trial. Parties agree that in case of early termination of this Agreement, they will in good faith try to make arrangements concerning the continuation of the treatment of the enrolled patients if such is in their medical best interest.

GOVERNING LAW AND DISPUTE RESOLUTION

This Agreement shall be governed by, and construed in all respects in accordance with the applicable laws without regard to its conflicts of laws rules. Any claims, controversies or disputes arising out of or in connection with this Agreement which cannot be settled amicably between the Parties, shall be subject to the exclusive jurisdiction of the competent court in Indore.

IN WITNESS WHEREOF, The Parties have duly executed this Agreement as of the date first written above.

Reviewing Committee: **Rectitude Ethics Committee (the institutional Ethics Committee), DNS Hospitals**

Signature:

Date: 23/09/2022

Name: DR. M.S. GUJRAL

Chairman
Rectitude Ethics Committee
INDORE

Malwanchal University INDORE

College Address : Index City, Near Khudel, NH-59A, Nemawar Road, Dist., INDORE (M.P.)- 452 016 Ph. 0731-4013600
City Office : 104, Trishul Apartment, 5, Sanghi Colony, A.B. Road, INDORE - 452008 Phone : 0731-4215757, Fax : 0731-4044715
E-mail : medical@indexgroup.co.in, deanindex1@gmail.com I website : www.indexgroup.co.in,

Title: Chairperson/Member Secretary, Rectitude Ethics Committee

Address for Notices: **Rectitude Ethics Committee**, DNS Hospitals Ltd., 14 Anoop Nagar, **A.B. Road, Near L.I.G. Square, Indore 452008, India**

Institute Signatory Authority: **Dr. Rajesh Jain**

Signature:

Date: 23/9/2022

Name: DR RAJESH JAIN

Title: **Director, DNS Hospitals Pvt.Ltd.,**

Address for Notices: **DNS Hospitals Pvt.Ltd., 14 Anoop Nagar,A.B. Road, Near L.I.G. Square, Indore 452008, India**

Investigator: **Dr. Amit Katlana**

Signature:

Date: 23/09/2022

Name: **Dr. Amit Katlana**

Dr. Amit Katlana
Surgery
Professor
Reg. No.- MP-4771

Title: **Principal Investigator**

Address for Notices: **Index Medical College Hospital & Research Centre at Index City, NH – 59A, Near Khudel, Nemawar Road, Indore, Madhya Pradesh 452016**

Institute Signatory Authority: **Dr. G. S. Patel**

Signature:

Date: 23/9/22

Dean
Index Medical College,
Hospital & R.C.,INDORE

Name: Dr G.S. Patel

Title: **Dean, Index Medical College Hospital & Research Centre**

Address for Notices: **Index Medical College Hospital & Research Centre at Index City, NH – 59A, Near Khudel, Nemawar Road, Indore, Madhya Pradesh 452016**

College Address : Index City, Near Khudel, NH-59A, Nemawar Road, Dist., INDORE (M.P.)- 452 016 Ph. 0731-4013600
City Office : 104, Trishul Apartment, 5, Sanghi Colony, A.B. Road, INDORE - 452008 Phone : 0731-4215757, Fax : 0731-4044715
E-mail : medical@indexgroup.co.in, deanindex1@gmail.com I website : www.indexgroup.co.in,



CLINICAL TRIAL AGREEMENT

This Clinical Trial Agreement [Hereinafter referred to as "Agreement"] is entered into on 06th Oct 2022 among.

Raptim Research Pvt. Ltd. a company originally incorporated in the year 2005 and registered under Companies act, 1956 as having one of its office is located at A-242, TTC Industrial Area, Near Mahape Depot, Mahape MIDC, Navi Mumbai-400701, Maharashtra, India, [Hereinafter referred to as "CRO"] of the first part.

Registrar
Malwanchal University
Indore (M.P.)

And

Dr. Amit Katlana Index Medical College Hospital & Research Center , Index City, NH 59A, Nemawar Road, Indore 452016. Madhya Pradesh-India..[Hereinafter referred to as "Principal Investigator"] of the Second part

And

Head of Institute, Index Medical College Hospital & Research Center , Index City, NH 59A, Nemawar Road, Indore 452016. Madhya Pradesh-India. [Hereinafter referred to as ""Institute"] of the third Part.

And

Canvass Clinical Research Services Pvt. Ltd B-303, Keshav Imperial, Opposite Shani Mandir, Sitabuldi, Nagpur 440012, Maharashtra, India Represented by Ms. Vijaya Bhakte [Hereinafter referred to as "SMO"] of the forth Part.

WHEREAS Sponsor, **Eugia Pharma Specialities Limited** (having its registered office at "(Sy No. 550, 551, 552, Kolthur(Village), Shameerpet(Mandal), Medchal- Malkajgiri District, Telangana , India) [Hereinafter referred to as "Sponsor"] wishes to conduct clinical trial entitled "A Multicentric, Open-label, Randomized, Two Period, Two Treatment, Two Sequence, Crossover, Multiple Dose, Steady state Bioequivalence Study of Pazopanib tablets 200 mg of Eugia Pharma Specialities Limited, India (Test) with VOTRIENT® (pazopanib) tablets 200 mg of Novartis Pharmaceuticals Corporation, USA (Reference) in adult patients with advanced renal cell carcinoma already receiving Pazopanib HCl tablets in standard therapy, and who are tolerating a stable dosing regimen of 800 mg/day (4 × 200 mg) under fasting conditions" **(Study Number CR200-18)** [Hereafter referred to as "Study"] has engaged CRO to conduct this study.

AND WHEREAS CRO has already identified the Principal Investigator based on his/her experience and expertise and also Principal Investigator has sought permission from the Institution to conduct this study in the premises of the Institution. Hence CRO is desirous of engaging the said Principal Investigator and Institute for carrying out the Study.

NOW, THEREFORE, in consideration of the premises and the covenants, enter into this Agreement and do hereby agree with each other to the following:

1) Statement of work

1.1) "Study" shall be deemed to be "Clinical Trial" as defined in rule-GSR-227 New drug CT rule 2019 (including all amendments from time to time till present).

1.2) Principal Investigator and Institute will be responsible to conduct this study with strict compliance to approved Protocol, ICH-GCP and applicable laws and regulations prevailing in the country where clinical trial is conducted giving utmost importance to protect rights, safety and well-being of clinical trials subject.

1.3) CRO shall provide Principal Investigator with a sufficient quantity of study supplies to conduct the Study at investigational site in timely manner. Institute and Principal Investigator shall use Study Supplies in clinical trial subjects only for the purpose to conduct the Study in accordance with the Protocol; All These study supplies includes such as Study drug(s) Investigational Product (IP) and related devices/instruments, equipment, diary cards, paper CRF or blank informed consent forms and remain the sole property of CRO, unless otherwise designated. The Institute and Principal Investigator will be responsible for the return of excess, unused study supplies to the CRO or at CRO's option towards completion of study or earlier termination or may inform in writing for destruction by Institute and provide destruction certificate. In either case expense will be paid by CRO.

1.4) Study Timelines: Study Timelines for the purpose of this Agreement will be in accordance with Protocol and as conveyed by CRO from time to time.

2) **Responsibilities And Obligations of the Principal Investigator**

2.1) The Principal Investigator will conduct the study in the Institute in accordance with approved protocol, New Drug CT Rule 2019 (including amendments from time to time). And Indian Council of Medical Research (ICMR) Guidelines along with Helsinki and The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Guidelines for international studies and all applicable laws and regulations prevailing in country during conduct of clinical trial.

2.2) Principal Investigator will have trained and experience staff as a part of his/her team throughout the study to perform study related activities after they have been trained on their role to be performed in the study. Principal Investigator may delegate and document delegation of his responsibilities to his/her team members who too will strict comply with obligations of Principal Investigator mentioned in section 2.2.

2.3) Principal Investigator will start performing study related activities only after fully execution of this Agreement by all parties who are signatory in this Agreement and after having IEC (Institute Ethics Committee) and regulatory approval are in place.

2.4) The Principal Investigator will ensure enrolment of trial participants after obtaining signed informed consent including audiovisual recording wherever applicable and also informing the provisions of adequate treatment and compensation for Serious Adverse Event (SAE) as per New Drug CT rule 2019 including amendments from time to time. In case of amendment to informed consent form (ascent form, if required), prompt consenting will be obtained by Principal Investigator on approved version of amendment consent form with liberty to trial subjects to decide on further continuation in the study.

2.5) Principal Investigator will recruit only those trial participants into study who meet all Inclusion and Exclusion criteria for the study provided in the approved Protocol.

2.6) The Principal Investigator will be responsible for submission of study documents from CRO to IEC to obtain approval for conduct of study and forwarding IEC communications to CROs within a week of receipt of response which may either be comments for the need of any change in protocol or Patient Information Sheet (PIS) or approval to conduct said study in the Institute.

Registrar
Malwanchal University

2.7) It will solely be Principal Investigator's responsibility to ensure trial participants are randomized correctly as per randomization schedule and administered Investigational Product (IP) only to assigned subjects enrolled in the trial as per Protocol. Principal Investigator will be responsible for proper account of receipt of IP; selection and storage of reserved (retention) samples; IP utilization by assigned subjects and return of unused IP to CRO/sponsor as well as prevent its use for any other purpose apart from Protocol.

2.8) The Principal Investigator shall report all serious and unexpected adverse events and/ or death to the Licensing Authority, CRO, and IEC as per New CT rule 2019 (including amendment from time to time)..

2.9) The Principal Investigator shall forward its report on Serious Adverse Event of Death after due analysis of all factors with his opinion to Chairman of IEC, Head of the Institute and the Licensing authority as per New CT rule 2019 (including amendments from time to time).

2.10) During and following a Clinical Trial Subject's participation in Study, the Principal Investigator shall ensure that prompt diagnosis and adequate medical care is provided to the participant (Clinical Trial Subject) for any adverse events.

2.11) The Principal Investigator will be responsible for keeping source of subject up to date, for proper and prompt filling of Case Report Form (CRF), preservation of investigation reports and recordings and resolution of any query generated from date being submitted. Where requested by CRO, Principal Investigator shall provide scan copy of source and other documents after masking subject's confidential information.

2.12) The Principal Investigator will make necessary arrangement for inspection of study related documents including signed informed consent form and Investigational Product (IP) etc. by CRO's monitor, official of regulatory agency or Institutional Ethics Committee (IEC) nominee.

2.13) In case of any deviation non-compliance/violation to approved Protocol, Principal Investigator will promptly document and notify to CRO and IEC.

2.14) The Principal Investigator will be responsible for obtaining IEC and CROs permission for storage of blood or tissue samples for future use.

The Principal Investigator shall not conduct additional research or obtain any additional biological samples (includes blood or tissue samples) apart from those specified in the Protocol from participating subjects unless it is approved in writing from CRO and applicable regulations plus in terms of subject safety. Once received, Principal Investigator will obtain necessary approval and permission for storage of these samples for future use.

2.15) The Principal Investigator will be responsible for providing progress report and any non-compliance report to Institutional Ethics Committee (IEC) and a copy to CRO within a week of occurrence or due date.

2.16) The Principal Investigator shall be responsible for obtaining CRO's permission before publication or conference presentation of any data.

2.17) Principal Investigator (PI) shall complete the Clinical Trial under his supervision as per the agreement and the Statutory provisions, but if for any reason he/she is unable to carry over the study it shall be his/her responsibility to hand over the study to either his/her Co-Principal Investigator (Co-PI) or to any of the Faculty members of the Institute as decided by the Head of Department of the PI or Director of Institute and obtain necessary approval of the Ethics Committee and the CRO.

3) Obligation and Responsibilities of the Institute:

3.1) To ensure study shall be conducted in compliance with the Protocol, Standard Operating Procedure (SOP) and applicable regulatory requirements.

3.2) Ensuring that the rights, safety and well-being of Clinical Trials Subject are protected.

3.3) Fulfillment of necessary obligations by Institutional Ethics Committee (IEC), Principal Investigator (PI) and supporting staff conducting said study.

3.4) Protection of confidentiality, rights, safety and wellbeing of clinical trial participants.

3.5) Provide necessary infrastructure support to PI to conduct study as required by Protocol.

3.6) Communicating with IEC and obtaining approval for the Clinical Trial Protocol, written informed consent and other trial related study documents. Ensure Principal Investigator communicates with IEC to obtain approval for the Clinical Trial Protocol, written informed consent and other trial related study documents including amendments.

3.7) Approval of study from EC within 6-8 weeks of receipt of Investigator's brochure, protocol including Patient Information Sheet (PIS) & Case Report Form (CRF), regulatory approvals, draft Clinical Trial Agreement (CTA), Insurance policy and IEC fee from CRO.

3.8) Approval of amendments if any of receipt of documents.

3.9) The confidentiality of record that could identify Clinical Trial subject should be protected and maintained.

3.10) Ensuring accuracy, completeness, legibility and timelines of the Data being reported to the CRO in Case Report Forms (CRFs) and in all required reports.

3.11) Safety reporting as per New Drug CT rule 2019(including amendments from time to time) and/or CRO policy.

3.12) Provide adequate treatment and compensation for Serious Adverse Event (SAE) to trial subjects and ensure compensation received from CRO are paid to these subjects.

3.13) Review of progress report, Data and Safety Monitoring Board (DSMB) report & Serious Adverse Event (SAE) from other centers and accordingly provide decision on termination of study or its extension beyond approved period.

3.14) Review of SAE at site and necessary action within the time frame decided by regulatory agencies. Review of SAE and ensure all necessary requirements including those of prevailing regulatory guidelines are fulfilled by Institute itself, Principal Investigator and IEC.

3.15) In case EC recommends of termination of study in view of safety and benefit of clinical trial subjects, Institute will ensure study is properly terminated by Principal Investigator as per CRO instructions while ensuring no risk to trial subjects,.

3.16) Provide adequate storage facility for biological samples including blood and tissue of clinical trial subjects in case Protocol requires it to be stored for future use.

3.17) Institutional clearance for samples to be sent abroad non-pharmacokinetic studies. Institutional clearance for samples to be sent abroad for analysis where required studies.

3.18) Facilitate visit of CRO's monitor or its representative or representative of regulatory agencies.

3.19) Upon request of the monitor, auditor, Institutional Ethics Committee or applicable regulatory authority, Institute should make available for direct access all requested trial related records including signed informed consent form.

3.20) Safeguarding Intellectual property rights (IPR) of CRO.

3.21) Archiving of data for 05 years after completion of all planned regulatory activities as per prevailing laws and regulations of that country (ies) for which study was conducted or as mentioned in the Protocol or for longer period if required by CRO/Regulatory agency).

3.22) Providing alternate Principal Investigator (PI) if PI unable to continue (which may include transfer, retirement etc).

3.23) Audited statement of utilization of Funds.

4) Obligation and Responsibilities of the Site Management Organization (SMO):

Institute and Principal Investigator (PI) have jointly appointed SMO to assist PI in effective management and execution of awarded clinical trial as per Protocol, Regulatory requirement and prevailing law. SMO will be first point of contact for all the conduct of trial related activities and will be responsible for ensuring smooth conduct of trial at the site including but not limited to responsibilities mentioned below. SMO shall be responsible for completion of all Regulatory responsibilities on behalf of PI and Institute. SMO shall also be responsible for providing infra-structure which includes but not limited to equipments, instruments, its calibrations, trained and experienced staff as per trial requirement. SMO shall be responsible for receipt, management, storage and shall be held responsible for accountability of all trial supplies provided to site for the purpose of trial. In addition, SMO shall have responsibility for disbursement of all the payment received under this agreement to PI, Institute, subjects and vendors and will relieve Sponsor/CRO from their obligations. Also Sponsor/CRO are not liable for payment to SMO for using their service.

4.1) Pre Trial:

a) Assist CRO/ sponsor during conduct of feasibility and site selection visit.

b) Provide necessary site documents for Regulatory and Ethics Committee (EC) submission.

c) Submit trial dossier on behalf of Principal Investigator (PI) to EC and follow up for approval.

d) Recruit qualified and experience site staff as per trial requirement and impart Protocol and other necessary trainings to ensure trial is conducted as per Protocol and applicable regulatory guidelines.

e) Identify local vendors where required for performing trial related activities and have agreements with them post approval from Sponsor/CRO.

f) Create source document template for data collection to ensure all relevant information can be captured.

g) Support Sponsor/CRO in conduct of Site Initiation Visit.

h) Identify potential patients required for enrollment into the study.

i) Have Site SOP in place.

4.2) During Trial

a) Assist PI in

- Conduct of informed consent process and its documentation.
- Conduct of Protocol specified activities during Screening, randomization, scheduled visits and follow-ups.
- Completion of source documentation and accurately and timely transcribing data from source to Case Report Form (CRF) with no error.
- Investigational Product (IP) management at site which includes receipt, accountability, storage, dispensing and reconciliation process.
- Conduct of trial with utmost adherence to Protocol, keeping deviation to minimum.
- Responding to findings generated by site monitor/auditors/Regulatory inspectors.

b) Have system and plans in place to avoid deviations.

c) Timely reporting of SAEs as per prevailing timelines.

d) Disbursement of payments to PI, Institute and subject including reimbursement.

e) Review completed CRF to minimize queries being generated by monitor and data management.

f) Regularly update site files and provide required documents to site monitor as and when required.

g) Ensure source, CRF, logs, site files are completed prior to planned site monitoring visit.

h) Assist Sponsor/CRO during monitoring visits, audits and inspections.

i) Timely resolving queries generated by monitor and data management group.

j) Manage clinical trial supplies to ensure at no given time there is shortage supplies at site.

k) Coordinate with EC for any notification/approval/update during the course of the trial.

l) Coordinate with vendors like local/central laboratory, imaging department thereby ensuring reports are available to investigators within specified timeframe.

4.3) Post Trial

a) Assist site monitor during close out visit.

b) Assist site in destruction of unused trial supplies and materials where required.

c) Notify EC about trial close out and submission of Clinical Study Report (CSR).

d) Ensure all time audit/inspection readiness and assist PI, Sponsor and CRO during audit and inspection.

e) Ensure trial documents are properly archived throughout archival period and can be easily retrieved whenever required.

f) Inform Sponsor/CRO in case of site inspection; change in PI responsibilities like transfer or retirement of PI from the Institute or his/her demise or any debarment.

5) Responsibilities and Obligation of the CRO

5.1) To provide investigator's brochure, Protocol, Case Report Form (CRF) draft Clinical Trial Agreement (CTA), Insurance policy from an Indian Insurance company and regulatory approvals including other study related documents and supplies.

5.2) To provide required devices/instruments and/or equipments to support Principal Investigator to conduct said study.

5.3) To provide adequate supplies of Investigational Product (IP) and comparator prepared under proper quality control as per regulatory norms.

5.4) To provide Insurance cover for treatment and compensation of Serious Adverse Event (SAE) including any diagnostic procedure performed and an undertaking to supplement any amount not covered by the Insurance Company. CRO will also provide copy of Policy to the Principal Investigator.

5.5) Assist Principle Investigator for storage of biological samples drawn as per Protocol for future study if requested by Principle Investigator.

5.6) Provide a copy of Clinical Study Report (CSR)/summary report at the end of study or at termination of the study to Principal Investigator and to IEC.

5.7) To submit a status report on the Clinical Trial to the Licensing Authority at the prescribed Periodicity.

5.8) Appropriately acknowledge Principal Investigator for his/her contribution in the study in any publication as deemed suitable by CRO.

5.9) To define and follow procedure for premature termination.

6) **Debarment**

Principal Investigator and Institution certifies that they and any of their facility or person attached to such facility whose services are used for conduct of study like laboratory are not debarred by Indian law or US law or by law of any country where submissions are planned to be made. Principal Investigator and Institution will promptly inform CRO of any such debar being aware during the course of study until one year post completion of this study or within 30 days from "Effective Date of Termination" mentioned in section 22.5 of this agreement and will extend full cooperation to CRO

7) **Financial Compensation**

7.1) CRO on behalf of Sponsor agrees that any injury or death or injury to child in-utero of the clinical trial subject occurring in clinical trial due to following reasons shall be considered as clinical trial related injury or death or injury to a child in-utero and the subject or his nominee, as the case may be, will be entitled to receive from the Sponsor financial compensation for such injury or death or injury to a child in utero as per the notification decided by of the Drug Controller General of India (DCGI) issued from time to time.

a) Adverse effect of Investigational Product(s);

b) Failure of Investigational Product to provide intended therapeutic effect;

c) For injury to a child in utero because of the participation of parent in clinical trial provided adequate method of contraception as specified in Protocol was used throughout the duration mentioned in the Protocol;

d) Any clinical trial procedures involved in the Study.

8) **Indemnification:**

CRO agrees to hold harmless Principal Investigator, his/her staff involved in clinical trial, Institution at which the study is conducted and the IEC that approved the study. CRO indemnifies them of any claim filed by subject or his/her legal representative or the nominee for any adverse event to subject due to participation in the study provided approved protocol was followed excluding negligence or misconduct by Principal Investigator, his/her staff or Institution or IEC . Principal Investigator will promptly inform CRO of any such notice and will extend full cooperation to CRO.

9) **Undertaking and Representation of Principal Investigator:**

Principal Investigator hereby represents that he/she has furnished an undertaking to Licensing Authority in the format given in New Drug CT rule 2019 including amendments from time to time.

Registrar
Malwanchal University

10) Undertaking and Representation of Institute:

Institute hereby represents that: - It has constituted the Ethics Committee (EC) as per the guidelines given in the Gazette of India & it has been registered with the Drug Controller General of India (DCGI) vide letter No: ECR/1600/Inst/MP/2021

10.1) EC SOP is in compliance with Good Clinical Practice (GCP) guidelines and applicable regulations:

10.2) It will ensure that EC will fulfills its responsibilities as per provisions of New Drug CT rule 2019 including amendments from time to time.

11) Undertaking and Representation of CRO:

CRO hereby understands and represents that: - It has furnished an undertaking on behalf of Sponsor along with the application for Clinical Trial Permission to the Licensing Authority to provide compensation in the case of clinical trial related injury or death for which subjects will be entitled to compensation; as per provisions of rule New Drug CT rule 2019.

12) Administration:

12.1) Overall responsibilities to conduct study at Institute will rest with Principal Investigator.

12.2) The following study plan will apply to the Study:

a) Institute's Enrollment Maximum (i.e. Total number of enrolled subjected expected from site) shall be as mentioned in annexure-A of this agreement. However, if the Institute and Principal Investigator are unable to enroll patients for the Study within 3-4 weeks of Site initiation CRO will be having the authority to change the Institute's Enrollment Maximum in a unilateral manner or close the site.

b) Subject to applicable law: CRO and Institute without any further obligation mutually may agree in writing to modify Institute's Enrollment Maximum at any stage.

c) All subject visits will be conducted as proposed in the Protocol. The CRO will be informed if a subject visit exceeds visit window period along with reason of delay.

Registrar
Malwanchal University
Indore (M.P.)

d) Case Report Forms ("CRFs") information associated with a subject's visit must be satisfactorily completed within 3 working days after the subject's visit or, if applicable, receipt of the subject's test results.

e) All Data Queries from CRO or Sponsor or from Data Management group as applicable must be completed and returned to CRO within a time frame mutually negotiated.

f) Any intentional changes of inclusion/exclusion criteria by the Principal Investigator or Study team without approval from CRO will not be the liability of CRO.

13) Trial Drug; Materials Transfer; Records Retention;

13.1) Investigational Product (IP)/device (instrument) or equipment:

a) Institute and Principal Investigator acknowledge that the investigational product or device (instrument) or equipment is owned or controlled by CRO on behalf of the sponsor and that neither the terms of this Agreement nor the Protocol, nor any activities conducted by Institute or Principal Investigator, shall be construed to grant to either Institute or Principal Investigator any rights in or to the Compound/ Investigational Product (IP).

b) CRO will provide the Investigational Product (IP) which includes test drug or reference drug to be administered to trial subjects as part of the Trial with no cost to Institute for administering or dispensing solely by or under the supervision of Principal Investigator or sub-investigator to trial subjects at the trial site in Strict compliance with the Protocol.

c) Principal Investigator shall be responsible to randomly select quantity of IP as directed by CRO/sponsor for 'Reserved (retention) samples' and its storage securely throughout the trial period to avoid its accidental usage.

d) Institute and Principal Investigator shall store and use Investigational Product (IP) solely to conduct the Trial in strict compliance with the Protocol and for no other purpose, and shall not transfer the Investigational Product (IP) to any third parties. Institute and Principal Investigator shall handle, store, ship and dispose of the

Registrar
Malwanchal

Investigational Product (IP) as directed by CRO and in compliance with all applicable laws, rules and regulations.

e) Institute and Principal Investigator will ensure empty and partially used Investigational Product (IP) container and any unused Investigational Product (IP) remaining at the trial close-out visit at the trial Site or upon early termination of this Agreement are either disposed of or returned to CRO in accordance with the Protocol or at CRO's option as directed by CRO at the time of site closure. All clinical retention IP samples will be stored at the clinical site or be stored at some 3rd party until further instructions by the sponsor for its destruction.

f) Neither Principal Investigator nor Institute will impose any obligation, express or implied, on CRO/Sponsor to purchase, prescribe, provide favorable formulary status for or otherwise to support trial product.

g) Unless specified in the Protocol, Principal Investigator will not modify the Investigational Product (IP) or its container. If the Institute policy requires any modification to the Investigational Product (IP) container, such modification must be approved in advance in writing by Sponsor.

13.2) Records Maintenance and Retention:

a) Principal Investigator and Institute will maintain clinical trial related records relating to Investigational Product (IP) and other trial subject documents including but not limited to, signed consent form and audiovisual documents if applicable, medical records, charts pertaining to individual trial subjects, "Case Report Forms ("CRF") accounting records, notes, laboratory reports, and data. Institution will permit Principal Investigator to retain these documents for a period of at least 05yrs or longer as mentioned in below Section-24, Record Keeping, after completion of all regulatory activity as per applicable laws and regulations for the country (ies) for which study was conducted or in accordance with Protocol or earlier termination of the trial or till the time CRO notifies to Principal Investigator in writing for return or destruction study documents.

14) Representation and Warranties

14.1) Principal Investigator and Institute represents and warrants that it has the legal authority to enter into this Agreement and that the terms of this Agreement are not in conflict with any other agreements to which it is legally bound. Institute shall ensure that Principal Investigator will not enter into any agreement or engage in any activities that would materially impair its or his /her ability to complete the trial in accordance with this Agreement and the Protocol.

14.2) Institute represents and warrants that the Principal Investigator is qualified as a medical practitioner under applicable laws and regulations.

15) Confidentiality

15.1) Institute will (and will cause Principal Investigator and trial personnel appointed by PI to) keep strictly confidential and not disclose to third parties all information provided by or on behalf of subject or of data that is generated, discovered, or obtained by any of the Party signatory to this agreement as a result of the trial (other than patient medical records), including the trial results, trial inventions and information related thereto (Confidential Information). Institute and Investigator will use, and will ensure trial personnel to use, Confidential Information only for purposes of the trial. The obligations of this Section will survive expiration or termination of this Agreement and can be maintained in good faith. Confidential Information will not include information that:

a) Is or becomes publically available through no fault of Investigator or Institution.

b) Was known to Principal Investigator or Institute without obligation of confidentiality prior to receiving it either directly or indirectly from other sources Under this Agreement, as demonstrated by written records predating the date it was learned by Investigator or Institute form other source.

c) Is disclosed to Principal Investigator or Institution by a third party without violation of law or any obligation of confidentiality; or

d) Can be shown by written records of Principal Investigator or Institution to have been independently developed by Principal Investigator or Institution without reference to or reliance upon any Confidential Information.

Registrar
Malwanchal University
Indore (M.P.)

15.2) Notwithstanding any other provision of this Agreement, Institute and Principal Investigator may disclose Confidential Information to the extent required.

a) To comply with an applicable law, rule regulation or government order, after prompt notice to CRO provided that Investigator and Institute cooperate with CRO efforts to limit such disclosure by appropriate legal means;

b) To protect any trial subject's safety or provide appropriate medical care for any trial subject, or to prevent a public health emergency with prompt notice to CRO

c) For purposes of insurance or reimbursement by a third party or pay for medical treatment of trial subject related to the procedures included in the Protocol.

16) Return of Confidential Information:

Upon either (i) the completion of the Trial or termination of this Agreement; or (ii) CRO's request in writing for any reason, Institute will immediately cease use of all Confidential Information, and will promptly either return to CRO or if instructed by CRO destroy all Confidential Information, including any copies, extracts, summaries, or derivative works thereof, and certify in writing to CRO the completion of such return and/or destruction, provided, however, that Institute may retain one copy of Confidential Information in its legal archives solely for the purpose of monitoring its surviving obligations under this Agreement.

17) Trial Results and Inventions:

17.1) CRO, on behalf of the sponsor, owns all data generated from the trial, trial results, Confidential information, Case Report Forms (CRFs) and all other information generated as a result of or in connection with the conduct of the trial, excluding Institution's patient medical records and Principal Investigator's personal notes and hereby grants to the Institute a nonexclusive, non–transferable, non-sub licensable right to use the trial results solely for its own internal, non-commercial research, patient care, and educational purposes.

17.2) All inventions, ideas, methods, works of authorship, know-how or discoveries that are made, conceived, or reduced to practice by Institute, Principal Investigator or trial personnel: (i) as a result of or in connection with the conduct of the trial (ii) that

Registrar

incorporate or use Confidential information: or (iii) that are directly related to the compound and in each case together will all intellectual property rights relating thereto (collectively, Trial Inventions"), will be the sole and exclusive property of CRO or its designee. Institute and Principal Investigator will promptly disclose all trial Investigations to CRO in writing and interest in all trial investigations to CRO or its designee. At CRO's request and expense, Institute shall take and shall cause Principal Investigator and trial personnel to take, all additional actions as it deems necessary taking into consideration interest of CRO and Sponsor in Trial Investigations or to obtain patents or otherwise protect the interest of CRO or its designee in Trial Investigations.

18) Payment:

18.1) In consideration for conducting the Study, CRO shall pay to Institute and Principal Investigator as described in Annexure-A. CRO will not make further payments, towards study visits, procedures, or other work associated with a Study subject if CRO determines that the clinical trial subject's data is not evaluable because of a violation of the Protocol by Principal Investigator or Study Staff.

18.2) CRO shall pay on a per subject cost for each satisfactorily completed subject (as defined below) in accordance with Annexure-A as attached to this Agreement. Only if a subject is discontinued for reason stipulated in the Protocol, the Institute and Principal Investigator shall be paid a prorated rate for work completed

a) Per Subject Costs: Payments will be made on per completed subject basis, in accordance with Annexure-A. The estimated total amount per clinical trial subject listed in Annexure-A is calculated for a clinical trial subject that completes all the study visits. Payment for Screening Visit shall be paid for consented clinical trial subjects in whom all screening procedures are performed. All the visit cost includes Institutional overhead, staff fees and applicable taxes from time to time, excluding GST.

b) The per subject costs is a fixed fee per subject which includes all costs and honoraria, including but not limited to:

Registrar
Maharshi University

- All study related activities such as conduct of visit assessment and CRF completion time and efforts of Principal Investigator/s and other Institute's study personnel including all manpower cost involved in the study conduct
- Site coordinator / Site Management Organization (SMO).
- Subject Travel Reimbursement / compensation.
- All Diagnostic test and other investigations (ECG, Chest X Ray, Spinal X Ray, etc)
- Housing or Hospital Stay including meals
- All Institutional overhead costs.
- Usage of instruments/ equipments which during the study should be having for proper instrument ID, their maintenance and calibration/annual maintenance record.
- Miscellaneous (telephone, fax, courier, storage cupboards and maintenance of Institute infrastructure).

c) Subjected to the terms of Protocol, a completed and evaluable subject means:

i) Who is enrolled for the Study according to inclusion and exclusion criteria and has completed all study visits with the Protocol specified procedures/assessments.

ii) For whom all sources, CRF and other Study related documents are completed as per protocol requirements

iii) For whom all Data are accurately and completely documented and transcribed in CRF.

iv) All data queries generated were resolved completely under mutually agreed timely manner.

18.3) Screen Failures/ Drop-outs: For drop-outs payment will be made by CRO on a pro-rated basis for the number of completed visits and for screen failure it will be according to details mentioned in Annexure-A

18.4) Institutional Ethics Committee: Apart from the payment mentioned in Annexure-A, CRO will pay for Institutional Ethics Committee fees.

18.5) Archival of study documents and reserved samples for a duration of 05 years after site closure will be paid as per details mentioned in Annexure-A.

Registrar
Malwanchal University

18.6) Hospitalization costs: Apart from study specific hospitalization, any hospitalization charges related to Serious Adverse Event (SAE) shall be paid by CRO on behalf of Sponsor to the clinical trial subject.

18.7) CRO will release the funds to Institute or Principal Investigator for each clinical trial subject as per the study schedule for completed visits. However, it will be the obligation of Principal Investigator to pay the clinical trial subject reimbursement on a pro rata basis study period wise.

18.8) Payment towards Actuals: Principal Investigator will be reimbursed for purchase of medicines as a part of standard of care or concomitant medication as per Protocol along with any ancillaries. Principal Investigator to provide a copy invoice or other documentation clearly substantiating that the expenditures were actual and reasonable.

18.9) The Principal Investigator will not receive any direct or indirect payment from subject(s) participating in the Study or third-party payers for any material, treatment or service that is required by the Protocol.

18.10) Refund of Payment: In the event there is a refund due to CRO at the time of termination of this Agreement by any party, the Institute agrees to remit the same to CRO within sixty (60) days of the effective termination date (definition of which is mentioned in Section 23 below).

18.11) Tax deduction: All fees and amounts listed are inclusive of applicable tax (TDS- Tax Deduction at Source) prevailing from time to time. Prevailing TDS rate will be deducted from each payment disbursed to the Institute for the Study as per the applicable existing tax laws in the country. Certificate for the tax deducted at source will be provided at the end of the financial year.

19) Use of other parties' names:

The Principal Investigator and Institute shall not use CRO/Sponsor name or the name of any party hereto in connection with any advertising or promotion of any product or service without the prior written permission from CRO/Sponsor.

20) No joint venture etc.

This Agreement shall not constitute, create, or in any way be interpreted as, a joint venture, partnership, or business organization of any kind.

21) Monitoring; Audit; Regulatory Inspection:

21.1) The Principal Investigator and Institute shall permit authorized personnel of the CRO/ CRO designate, any Regulatory Authority and EC to inspect the facilities of the Investigational Site before, during and after the Study.

21.2) The Principal Investigator and Institute shall notify to the CRO immediately by letter or mail if the Drugs Controller General-India, or any other governmental or regulatory authority requests permission to or does inspect the Principal Investigator and Institute's facilities or research records relating to this study whenever and will provide in writing to the inspecting authority copies of all materials, correspondence, statements, forms and records which the Principal Investigator and Institute receives, obtains, or generates pursuant to any such study.

21.3) The Principal Investigator and Institute will permit the CRO to; (a) Examine, inspect and audit the work performed as a part of the study and the facilities, systems, instruments and equipment used with which the study related activities are conducted under this Agreement as a part of study. (b) Inspect and retrieve documents and records related to such Study.

21.4) The Principal Investigator will promptly resolve any discrepancies that are identified in Study data or subject's medical record during monitoring, audit or during regulatory inspection.

21.5) The Principal Investigator will promptly intimate to CRO about findings generated from audit or regulatory inspection and may take assistance of CRO in responding to the findings.

21.6) The obligations of this Section shall beyond the expiration or termination of this Agreement and can be maintained in good faith.

22) Term; Waiver; Severability (The trial on its time extended):

22.1) This Agreement will become effective and fully executed after by the last signatory signs the agreement and shall continue in effect for the full duration of the study according to the Protocol unless extended by consent of all parties to this Agreement or sooner earlier terminated in accordance with the provisions of this Agreement.

22.2) This Agreement will be in force for a period of the trial and its time extended from the date of its signing. The term of this Agreement may be extended by consent of all parties to this Agreement.

22.3) Unless earlier terminated in accordance with the provisions of this Agreement, the term of this Agreement shall commence on the Effective Date. The Date of execution of this Agreement shall be the Effective Date.

22.4) None of the obligations under this agreement will be assigned by Principal Investigator and Institute to another without prior written approval from CRO.

22.5) This Agreement may be terminated by any party upon giving at least a thirty (30) days written notice to that effect to the other parties. The day following the 30th day of such notice shall be "Effective Date of Termination".

22.6) Any notice under this Agreement will be given in writing to:

Raptim Research Private Limited and to Principal Investigator at their address provided in signatory

23) Effect of termination

This agreement will be terminated upon any of the following events:

23.1) By EC or Regulatory agency (DCGI).

23.2) Early termination of study by Sponsor or Principal Investigator or Institute or by CRO.

23.3) Upon notice of termination of this Agreement by either Institute or CRO or Principal Investigator, Principal Investigator shall cease enrolling clinical trial subjects into the study, and shall proceed to discontinue ongoing subjects from study as soon as is medically practicable.

23.4) Upon notice of termination of this Agreement by Institute or CRO or Principal Investigator, Institute and/or Principal Investigator shall use reasonable efforts to revoke

any financial obligations incurred and shall avoid incurring any additional costs in connection with the study. Institute shall be compensated only for study-related work actually performed or reimbursed only for expenses actually and reasonably incurred through the effective date of termination which CRO has agreed to pay as part of the study under this Agreement. If, upon the Effective Date of Termination, CRO has advanced funds which remain unutilized or surplus, Institute shall repay such funds within sixty (60) days of the Effective Date of Termination. In the event Institute fails to repay such funds in a timely manner, CRO may deduct an equivalent amount from any payment then or later due from CRO to Institute under this or any other arrangement between the parties.

23.5) Upon termination of this Agreement, all unused Materials and all CRO Confidential Information (except for such records that Institute is required by law or regulation to retain) in Institute's or Principal Investigator's possession shall be promptly delivered to CRO at CRO's expense, or, at CRO's option, destroyed with the destruction certified in writing.

24) Record keeping

Institute and Principal Investigator shall retain for archival of all records and documents pertaining to the study under appropriate storage conditions so that they are preserve them for a period of 05years after completion of all regulatory activity as per applicable laws and regulations for the country (ies) for which study was conducted or in accordance with Protocol unless CRO provides in writing for return or destruction of records and documents prior to retention period. At the end of retention period if no response is received from CRO, Institute can forward all study related documents retained by Institute to CRO at CRO's expense. CRO can request Institute to retain study related documents for longer period at CRO's expense for which Agreement will be signed. Institute may choose to retain these study related documents for longer time on request of CRO at different location from earlier one with written approval from CRO.

Registrar

25) Publication

The parties acknowledge that the Sponsor will retain ownership of all original data generated from this study. Data generated during the Clinical Trial Study is the sole property of the Sponsor & CRO. Therefore, Principal Investigator agrees not to publish or present the results or any information derived from the study but Sponsor may decide to include his/her name in any publication either as author or as participant in the study.

26) Miscellaneous

Parties to this Agreement shall comply with the current provision of New Drug CT rule 2019 including amendments from time to time. For providing insurance to Clinical Trial Subjects in case of injuries or death, the Sponsor/CRO to this Agreement have tied up with insurance company This insurance shall be extended from time to time till the expiry of Agreement.

27) Governing Law

The validity, interpretation, and performance of this Agreement shall be governed and construed in accordance with the laws of INDIA as applicable in the State of Mumbai.

28) Jurisdiction

The place of jurisdiction for any dispute or claim before a court or an arbitrator shall be Mumbai notwithstanding any other provision to the contrary in any law in this regard.

29) Arbitration

All disputes or claims whatsoever arising out of or in respect of the terms and conditions of this agreement or relating to the admissibility or liability or quantity of compensation or damages payable to or by any of the parties to this agreement to the trial subject or his/her legal representative or the nominee or by one party against another shall be referred by the aggrieved party or person to the arbitration of a sole arbitrator to be appointed by the Chairman of the Institutional Ethics Committee of the Institute within 30 days of the receipt of a written request by the aggrieved. The Indian Arbitration and conciliation Act 1996 as amended from time to time shall be applicable to such arbitration proceedings subject to the exception that the trial subject or his/her legal representative or the nominee shall not be

Registrar

liable to pay the cost of arbitration. The award of the arbitrator shall be final and binding on all the parties thereto.

30) Amendment

This Agreement may only be amended by the mutual written consent of the parties hereto. The parties agree that this Agreement constitutes the sole, full and complete Agreement by and between the parties and supersedes all other written and oral Agreements and representation between the parties with respect to the said study. No amendments, changes, additions, deletions, or modifications to or of this Agreement shall be valid unless reduced to writing and signed by the parties.

Acceptance of Agreement:

All the below signatories confirm that they have read and understood all the clauses of this Agreement:

Principal Investigator Name & Address Of PI: Dr. Amit Katlana Index Medical College Hospital & Research Center ,Index City, NH 59A, Nemawar Road, Indore 452016, Madhya Pradesh-India	**Institution Signatory Name, Address & Designation: Head of Institute** Index Medical College Hospital & Research Center ,Index City, NH 59A, Nemawar Road, Indore 452016, Madhya Pradesh-India
Signature and date: 31/10/2022 **Stamp** Dr. Amit Katlana	**Signature and date:** 31/10/22 **Stamp**
Dr. Chirag Shah **Designation: Head of Clinical Operation** **Raptim Research Pvt. Ltd.** A-242, TTC Industrial Area, Near Mahape Depot, Mahape MIDC, Navi Mumbai-400701, Maharashtra, India	**SMO Name, Address & Designation:** **Ms. Vijaya Bhakte** Canvass Clinical Research Services Pvt. Ltd B-303, Keshav Imperial, Opposite Shani Mandir, Sitabuldi, Nagpur 440012, Maharashtra, India
Signature and date: 14/Oct/2022 **Stamp** Raptim Research Limited	**Signature and date:** 05-NOV-2022 **Stamp** Canvass Clinical Research Services Pvt. Ltd.

Registrar
Malwanchal University

The research grant payments will be made to the following payee:

Payee Details: SMO (Site Management Organization)

Payee Name (Account name)	**Canvass Clinical Research Services Pvt. Ltd**
Account Number	1667102000010636
Bank Name	IDBI BANK
Branch Name& Address	IDBI Bank Ltd. Ground Floor. Plot No.9. Kamptee RD. Near Lamba Petrol Pump & Punjab National Bank. Nagpur 440017. MH. India
Swift/IFSC Code	IBKLINBBNGP/IBKL0001667
PAN Number*	AAICC0445L
#GST No. if any:	27AAICC0445L1ZK

Registrar
(M.P.)

ANNEXURE- A: INVESTIGATOR GRANT PER COMPLETED SUBJECT

a) Total number of enrolled subjects expected from site: **10** (referred as Institute's Enrollment Maximum).

b) For every Screen Failure subject who could not proceed for Randomization into the Study as per the criteria of the Protocol, **Rs.10,000/- INR** (in words "Ten Thousand Rupees Only") shall be paid which shall be inclusive of all charges. After which, no payment shall be paid additional screen failure subjects apart from subject's travel compensation.

c) On completion of entire study as per Protocol, **Rs.2,14,000/-** (in words "Two lac fourteen thousand rupees only") shall be paid including Institutional Overhead charges.

Visit	PI Reimbursement	CRC Reimbursement	Patient Hospitalization Charges	Local lab investigation	Phlebotomist Charges	Visit Charges Total	Other Charges including Institutional Overhead (10 %)	Total	Grand Total
Screening	20000	1000	0	2000	1000	24000	2000	26000	191500
End of Period 1	30000	2000	10000	8000	3000	53000	3000	56000	
End of Period 2	30000	2000	10000	8000	3000	53000	3000	56000	
End of Study	45000	2000	0	2000	00	49000	4500	53500	

Patient Reimbursement:

Screening	End of Period 1	End of Period 2	End of Study	Total
1500	10000	10000	1000	22500

d) **Rs.50000/-** towards archival charges of study documents and reserved samples for a period of 05 years after site close-out will be paid in addition to above payments.

e) No other payments shall be made to Investigator and or Institution apart from Institutional Ethics Committee Fees which shall be paid on submission of invoice.

f) Above grant is inclusive of subject travel and compensation, hospitalization charges, subject's meal, local laboratory assessments as per Protocol, required infra-structure for conduct of this study, calibration/maintenance cost for study related equipments,etc. For

further details, please refer **section 18** of this agreement that covers all expenses under Per Subject Cost.

g) GST of 18% shall be additional to above mentioned Per Subject fees.

h) Per Subject fees shall be paid once Data Management and Quality Assurance confirms that there is no query in the retrieved CRF pages.

i) 20% of the Per Subject fees shall be paid after data base lock but before site closure.

j) Invoice must be submitted to CRO monitor for all costs to be paid by CRO.

k) All undisputed invoices shall be paid within 45 days of receipt.

l) No screen failure charges shall be paid in the absence of a documented screening visit.

Registrar
Dhanwanchal University
Indore (M.P.)

AMENDMENT TO CLINICAL TRIAL AGREEMENT FOR CHANGE OF PAYEE DETAILS

Further toCLINICAL TRIAL AGREEMENT (CTA) executed on 06/Oct/2022 between

Raptim Research Pvt. Ltd a company originally incorporated in the year 2005 and registered under Companies act, 1956 as having one of its office is located at A-242, TTC Industrial Area, Near Mahape Depot, Mahape MIDC, Navi Mumbai-400701, Maharashtra, India, [Hereinafter referred to as "CRO"] of the First part.

And

Dr. Amit Katlana Index Medical College Hospital & Research Center, Index city, NH 59A, Nemawar Road, Indore 452016, Madhya Pradesh, India. [Hereinafter referred to as "Principal Investigator"] of the Second part

And

Head of Institute, Index medical College Hospital & Research Center, Index city, NH 59A Nemawar Road, Indore 452016, Madhya Pradesh, India [Hereinafter referred to as ""Institute"] of the Third Part.

And

Canvass Clinical Research Services Pvt. Ltd B-303, Keshav Imperial, Opposite ShaniMandir, Sitabuldi, Nagpur 440012, Maharashtra, India Represented by Ms. Vijaya Bhakte [Hereinafter referred to as ""SMO" of the fourth Part.

For conduct of clinical trial " A Multicentric, Open-label, Randomized, Two Period, Two Treatment, Two Sequence, Crossover, Multiple Dose, Steady state Bioequivalence Study of Pazopanib tablets 200 mg of Eugia Pharma Specialities Limited, India (Test) with VOTRIENT® (pazopanib) tablets 200 mg of Novartis Pharmaceuticals Corporation, USA (Reference) in adult patients with advanced renal cell carcinoma already receiving PazopanibHCl tablets in standard therapy, and who are tolerating a stable dosing regimen of 800 mg/day (4 × 200 mg) under fasting conditions."
(Study Number: CR200-18 [Hereafter referred to as "Study"]

As per Principal Investigator's request, the SMO which was part of the agreement initially will be removed from this agreement as a Payee because the SMO wants to voluntarily withdraw from this agreement. Hence, there is a change in Payee details which were included in previously executed CTA dated 06/Oct/2022 and the payments related to the study will be made into Head of the Institute and Principal Investigator's accounts separately as per CTA. We would like to update Payee details in the agreement to be read as:

Head of the Institute:

Bank Name - Bank of India
Branch name - Index Medical College branch
Account Number - 885620110000071
IFSC code - BKID0008856

Registrar
Awanchal University
Indore (M.P.)

Principal Investigator- Dr. Amit katlana:
Bank name - State Bank of India
Account Number - 53002530103
IFS code - SBIN0030344

All the terms and condition including responsibilities of sponsor will remain the same as mentioned in the executed CTA.

Acceptance of Agreement:

All the below signatories confirm that they have read and understood all the clauses of this Agreement:

Principal Investigator Name & Address Of PI:

Name of PI: Dr. Amit Katlana

Name of Institute with address and pin code: Index Medical College Hospital & Research Center, Index city, NH 59A, Nemawar Road, Indore 452016, Madhya Pradesh, India.

Signature and date:

Dr. Amit Katlana
Physician
Regd. No. - MP-4771

30/5/23

Stamp

Institution Signatory Name, Address & Designation.

Name of signatory: Dr.G. S. Patel

Name of Institute with address and pin code: Index medical College Hospital & Research Center, Index city, NH 59A, Nemawar Road, Indore 452016, Madhya Pradesh, India

Signature and date:

23/05/23

Stamp

Raptim Research Private Limited:

Dr. Chirag Shah

Designation: Head - Clinical Operations

Raptim Research Pvt. Ltd.

A-242, TTC Industrial Area, Near Mahape Depot, Mahape MIDC, Navi Mumbai-400710, Maharashtra, India

Signature and date:

Stamp

Dr.Chirag Shah

Digitally signed by Dr.Chirag Shah
DN: cn=Dr.Chirag Shah, o=Raptim Research Pvt.Ltd, ou, email=chirag.shah@raptimresearch.com, c=IN
Date: 2023.05.18 10:15:00 +05'30'

Registrar
Malwanchal University
Indore (M.P.)

RECTITUDE ETHICS COMMITTEE

DNS HOSPITALS
Your Health, Our Mission

Date: 13 Oct 2022
To,
Dr. Amit Katlana
Principal Investigator,
Index Medical College & Hospital, Indore.

Reference: CR200-18

Subject: Ethics Committee Approval to conduct the above referenced study at Index Medical College & Hospital, Indore

Dear Dr. Katlana,

The meeting of Rectitude Ethics Committee, DNS Hospitals, 14 Anoop Nagar, L.I.G Square, A.B.Road, Indore,MP was held on 30 Sep 2022 17:15 at room no.314,3rd flr to review and discuss on your application dated 28 Sep 2022, to conduct proposed study

"A Multicentric, Open-label, Randomized, Two Period, Two Treatment, Two Sequence, Crossover, Multiple Dose, Steady state Bioequivalence Study of Pazopanib tablets 200 mg of Eugia Pharma Specialities Limited, India (Test) with VOTRIENT® (pazopanib) tablets 200 mg of Novartis Pharmaceuticals Corporation, USA (Reference) in adult patients with advanced renal cell carcinoma already receiving Pazopanib HCl tablets in standard therapy, and who are tolerating a stable dosing regimen of 800 mg/day (4 × 200 mg) under fasting conditions" at Index Medical College & Hospital,Indore

The following members of the EC were present during the meeting

Dr. M.S Gujaral	Chairperson
Dr. Neeraj Gupta	Member Secretary
Mr.Prashant Wadagbalkar	Basic Medical Scientist
Dr. Harish Tourani	Scientific Member
Dr.Taha Sethjiwala	Clinician
Mr. Nagendra Singh Sisodiya	Legal Expert
Ms.Chanchal Salaria	Social Scientist
Mr. Naresh Choudhary	Lay person

The following documents were reviewed ,discussed & approved during the meeting:

Sr. No.	Documents	Version	Date
1	Protocol	Version 1.0, Amendment- 02	20-01-2022
2	Product Label	NA	Feb-2022

Registrar

3	Investigator Undertaking	NA	02 Sep2022
4.	Protocol Signature Page	NA	02 Sep 2022
5	Principal Investigator CV & MRC	NA	02 Sep 2022
6	Declaration for providing standard care	NA	27 Sep 2022
7.	Insurance Policy Document (Policy No 61220036210500000010)	NA	Valid from 05-10-21 to 04-10-22
8	ICF English	Version 1.0, Amendment 03	01-04-22
9	Informed Consent Form- Hindi (Translated from English to Hindi)	Version 1.0, Amendment 03	06-04-22
10.	ICF translation Certificate- English to Hindi	NA	06-04-22
11.	Informed Consent Form English (Back Translated from Hindi to English)	Version 1.0, Amendment 03	06-04-22
12.	ICF back translation Certificate- Hindi to English	NA	06-04-22
13.	Subject diary	Version 1.0	21-02-22
14.	Subject diary for stabilization	Version 1.0	21-02-22
15.	Subject Diary-Hindi (Translated from English to Hindi)	Version 1.0	03-03-22
16.	Subject Diary English (Back Translated from Hindi to English)	Version 1.0	03-03-22
17.	Diary translation Certificate- English to Hindi	NA	03-03-22
18.	Diary Back translation Certificate- Hindi to English	NA	03-03-22
19.	Subject Diary for Stabilization-Hindi (Translated from English to Hindi)	Version 1.0	03-03-22
20.	Subject Diary for stabilization English (Back Translated from Hindi to English)	Version 1.0	03-03-22

Registrar

21.	Diary used for Stabilization translation Certificate- English to Hindi	NA	03-03-22
22.	Diary used for stabilization Back translation Certificate- Hindi to English	NA	03-03-22
23.	eCRF Final	NA	13 Jul 2022
24.	DCGI Approval Letter (Amendment in BE NOC & Form 11)	NA	15-07-21
25.	DCGI Approval Letter	Version 1.0, Amendment 02	28-02-22
26.	Draft CTA	NA	NA

During discussion EC raised some queries & the same were resolved/responded

Comments: -

Validity of this approval letter is for a period of one year.

Type of review-New Review

Remarks/ Suggestions:

The IEC/IEB hereby approves the research proposal to be conducted in its presented form only.

The IEC/IRB expects to be informed immediately (within 24 hours) in case of any Serious Adverse Events (SAE), any changes in the protocol and patient information or informed consent and to be provided with a copy of the final report.

The IEC/IRB expects to be informed about study related information (new or changed or updated) that may affect safety of subjects and/or conduct of the study.

The IEC/IRB expects to be informed about the progress of the study at least six (06) months once from date of its first approval letter and/or case-by-case basis for pharmacodynamic study, pharmacokinetic study, epidemiological study, COHORT study etc.

Member of IEC/IRB will have right to monitor study site and conduct of study with prior intimation.

Notification letters regarding initiation, on-going and completion of study should be informed.

RECTITUDE ETHICS COMMITTEE

DNS HOSPITALS
Your Health, Our Mission

Yours Sincerely,

13/OCT/2022.

Dr. Neeraj Gupta

Member Secretary

Rectitude Ethics Committee

File No. BE-EXPORT/20/000807

सत्यमेव जयते

DIRECTORATE GENERAL OF HEALTH SERVICES
Central Drugs Standard Control Organization
(BA/BE Division for Export)

FDA BHAWAN, KOTLA ROAD,
ITO (Near Bal Bhawan), New Delhi
Date:16-JAN-2023

To,

M/s Eugia Pharma Specialities Limited, EUGIA
Pharma Specialities Limited Sy No 550 551 552
Kolthur (V) Shameerpet (M) Hyderabad -
500072

Sub: Bioequivalence studies of of Pazopanib Tablets 200 mg-reg.

Ref: Your File Application is BABE/PostAppr/2023/23111 Dated :09-JAN-2023.

Sir,

With reference to subject cited above and based on the documents submitted by you, the Permission to conduct bioequivalence study in Form CT-07 bearing no. BE-EXPORT/20/000807 and the Import Licence in Form CT-17 bearing no. TL/BE-EXPORT/20/001098 dated 14-JUL-2020 issued by this Directorate to you for conducting Bioequivalence study for export of the drug of Pazopanib Tablets 200 mg is hereby amended as below:-

Amendment in Form CT-07 and Form CT-17: -

For:	Read:
NA	NA

In addition to existing sites, below mentioned additional study sites are included:

Registrar
Malwanchal University
Indore (M.P.)

Name and address of study centre:	Ethics Committee details:	Principal Investigator Name
HCG CANCER CENTRE, SHIPRA PATH 52/36, WARD 27, SECTOR 5, MANOSAROVAR, JAIPUR-302020, RAJASTHAN, INDIA.	HCG EL Jaipur Institutional Ethics Committee Healthcare Global Enterprises Limited Shipra Path, 52/36, Ward 27, Sector 5 Mansarovar Shipra Jaipur Rajasthan -302020 India.	Dr. B.S. Ankit Nehra.
Index Medical College Hospital and Research Centre, Index city NH 59A, Nemawar Road, Indore 452016, Madhya Pradesh, India.	Rectitude Ethics Committee DNS Hospitals Pvt. Ltd.14 Anoop Nagar L.I.G Square, A.B.Road , Indore Madhya Pradesh -452008 India.	Dr. Amit Katlana
Oncura Hematology and Oncology Care, 3rd Floor, Mahavir Centre, 47/48, Above Golden Punjab Restaurant, Sector 17, Vashi, New Mumbai-400703	Institutional Ethics Committee of Aayush Hospital 102-1,1st Floor, Laxman Arcade Vivekanand Co-op Hsg 90 Feet Road Dharavi Mumbai City Maharashtra - 400017 India.	Dr. Salil Patkar
Latur Super speciality speciality Pvt Ltd., Garud Chowk, Nanded Road, Latur-413512.	Instututional Ethics Committee, GMC, LATUR, MH Government Medical College, Latur, MH ,Near Rajasthan High school Latur Near Rajasthan Latur (India) -413512 India	Dr. Ajay Punpale
Marthwada Cancer Hospital and Research Institute, Plot no.2 Dyaneshwar Nagar, Infront of Stadium Garkheda, Aurangabad 431001	Ethics Committee of Ishwar Institute of Health Care 3rd Floor, Plot No.07, Gut No. 6/1 Padhegaon, Beside Panjabi Bhavan Jaysingpura Aurangabad Maharashtra-431002 India	Dr. Tushar Mule

All the other conditions of the Form CT-07 & Form CT-17 granted by this office shall remain unchanged.

Further, you are hereby directed to follow any other directives issued by Government of India and respective State Government from time to time with respect to COVID-19.

Yours faithfully,

Digitally signed by ARUP KUMAR CHATTERJEE
Date: 2023.01.16 15:52:44 +05'30'

(A.K.Chatterjee)

Asst. Drugs Controller (I)

Registrar